Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Moreover, NICE says there is no data to compare Keytruda plus chemo to the combination of Roche's rival cancer immunotherapy Tecentriq (atezolizumab) and chemo – which was previously recommended ...

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

Catherine Cooke is one of about 350 Kiwi women diagnosed with triple negative breast cancer each year. The only targeted treatment, the drug Keytruda, is unfunded for early-stage cancer like Cooke’s.

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer. Among patients with previously untreated locally advanced or ...

Summit Therapeutics stock is off to a slow start in 2025, but it still trades at a massive $13 billion valuation. The biotech ...

The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.

The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...

The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.

Overall, from early October 2024 to the present day, various combinations of Keytruda with Pfizer's (PFE) Padcev, chemoradiotherapy, or chemotherapy drugs have received several regulatory ...